Total Funding
35
22
Total FundingSeed raised
Growth Score
-3 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
158979
Hercules Pharmaceuticals is a bio tech Start up
- David Sherr: Chief Scientific Officer
- Bart Wuurman: CEOPast Role: DDF Ventures, Managing Director and Portfolio Company CEO
About the Company
Hercules is a biopharmaceutical company developing an innovative, oral, non-toxic drug therapy for chronic treatment of patients with Triple Negative Breast Cancer, and other solid tumors.
The company has demonstrated that blocking the Aryl hydrocarbon Receptor in solid tumors could: Enhance the response of the immune system to cancer
Reduce the chance of future relapses by reducing the number of Cancer Stem Cells Reduce metastatic behavior Reduce agression of existing cancer Make cancer cells more sensitive to standard chemotherapy
Hercules have discovered novel anti-cancer drugs that block the Aryl Hydrocarbon receptor and is now testing these products in preparation for clinical trials.
